Annual EBITDA
-$165.42 M
-$8.20 M-5.22%
December 31, 2023
Summary
- As of February 7, 2025, BTAI annual EBITDA is -$165.42 million, with the most recent change of -$8.20 million (-5.22%) on December 31, 2023.
- During the last 3 years, BTAI annual EBITDA has fallen by -$83.47 million (-101.85%).
- BTAI annual EBITDA is now -7702.88% below its all-time high of -$2.12 million, reached on December 31, 2016.
Performance
BTAI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.78 M
-$5.26 M-116.34%
September 30, 2024
Summary
- As of February 7, 2025, BTAI quarterly EBITDA is -$9.78 million, with the most recent change of -$5.26 million (-116.34%) on September 30, 2024.
- Over the past year, BTAI quarterly EBITDA has increased by +$8.96 million (+47.80%).
- BTAI quarterly EBITDA is now -1752.84% below its all-time high of -$528.00 thousand, reached on March 31, 2017.
Performance
BTAI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$56.15 M
+$37.37 M+39.96%
September 30, 2024
Summary
- As of February 7, 2025, BTAI TTM EBITDA is -$56.15 million, with the most recent change of +$37.37 million (+39.96%) on September 30, 2024.
- Over the past year, BTAI TTM EBITDA has increased by +$109.27 million (+66.05%).
- BTAI TTM EBITDA is now -10535.23% below its all-time high of -$528.00 thousand, reached on March 31, 2017.
Performance
BTAI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
BTAI EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.2% | +47.8% | +66.0% |
| 3 y3 years | -101.8% | +63.4% | +44.7% |
| 5 y5 years | -729.4% | -9.9% | -69.5% |
BTAI EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -55.2% | at low | -116.3% | +81.1% | at high | +71.7% |
| 5 y | 5-year | -404.5% | at low | -116.3% | +81.1% | -69.5% | +71.7% |
| alltime | all time | -7702.9% | at low | -1752.8% | +81.1% | <-9999.0% | +71.7% |
BioXcel Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.78 M(+116.3%) | -$56.15 M(-40.0%) |
| Jun 2024 | - | -$4.52 M(-80.4%) | -$93.53 M(-32.8%) |
| Mar 2024 | - | -$23.11 M(+23.3%) | -$139.18 M(-15.9%) |
| Dec 2023 | -$165.42 M(+5.2%) | -$18.74 M(-60.3%) | -$165.42 M(-16.7%) |
| Sep 2023 | - | -$47.16 M(-6.0%) | -$198.49 M(+4.8%) |
| Jun 2023 | - | -$50.17 M(+1.7%) | -$189.35 M(+8.1%) |
| Mar 2023 | - | -$49.35 M(-4.7%) | -$175.18 M(+11.4%) |
| Dec 2022 | -$157.22 M(+47.5%) | -$51.81 M(+36.3%) | -$157.22 M(+19.6%) |
| Sep 2022 | - | -$38.02 M(+5.6%) | -$131.42 M(+9.4%) |
| Jun 2022 | - | -$36.00 M(+14.7%) | -$120.14 M(+7.6%) |
| Mar 2022 | - | -$31.39 M(+20.7%) | -$111.66 M(+4.8%) |
| Dec 2021 | -$106.59 M(+30.1%) | -$26.01 M(-2.7%) | -$106.58 M(+4.9%) |
| Sep 2021 | - | -$26.73 M(-2.9%) | -$101.60 M(+2.0%) |
| Jun 2021 | - | -$27.52 M(+4.6%) | -$99.56 M(+6.6%) |
| Mar 2021 | - | -$26.30 M(+25.0%) | -$93.40 M(+14.0%) |
| Dec 2020 | -$81.95 M | -$21.04 M(-14.8%) | -$81.95 M(+18.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$24.70 M(+15.6%) | -$69.22 M(+29.6%) |
| Jun 2020 | - | -$21.36 M(+43.8%) | -$53.42 M(+31.5%) |
| Mar 2020 | - | -$14.86 M(+79.0%) | -$40.61 M(+22.6%) |
| Dec 2019 | -$32.79 M(+64.4%) | -$8.30 M(-6.8%) | -$33.14 M(+3.1%) |
| Sep 2019 | - | -$8.90 M(+4.1%) | -$32.14 M(+13.4%) |
| Jun 2019 | - | -$8.55 M(+15.8%) | -$28.35 M(+23.0%) |
| Mar 2019 | - | -$7.38 M(+1.1%) | -$23.04 M(+15.5%) |
| Dec 2018 | -$19.95 M(+339.7%) | -$7.30 M(+42.9%) | -$19.95 M(+31.5%) |
| Sep 2018 | - | -$5.11 M(+57.7%) | -$15.17 M(+38.2%) |
| Jun 2018 | - | -$3.24 M(-24.4%) | -$10.97 M(+32.3%) |
| Mar 2018 | - | -$4.29 M(+69.7%) | -$8.29 M(+82.9%) |
| Dec 2017 | -$4.54 M(+114.0%) | -$2.53 M(+175.8%) | -$4.54 M(+125.7%) |
| Sep 2017 | - | -$916.00 K(+62.1%) | -$2.01 M(+83.8%) |
| Jun 2017 | - | -$565.00 K(+7.0%) | -$1.09 M(+107.0%) |
| Mar 2017 | - | -$528.00 K | -$528.00 K |
| Dec 2016 | -$2.12 M | - | - |
FAQ
- What is BioXcel Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for BioXcel Therapeutics?
- What is BioXcel Therapeutics annual EBITDA year-on-year change?
- What is BioXcel Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for BioXcel Therapeutics?
- What is BioXcel Therapeutics quarterly EBITDA year-on-year change?
- What is BioXcel Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for BioXcel Therapeutics?
- What is BioXcel Therapeutics TTM EBITDA year-on-year change?
What is BioXcel Therapeutics annual EBITDA?
The current annual EBITDA of BTAI is -$165.42 M
What is the all time high annual EBITDA for BioXcel Therapeutics?
BioXcel Therapeutics all-time high annual EBITDA is -$2.12 M
What is BioXcel Therapeutics annual EBITDA year-on-year change?
Over the past year, BTAI annual EBITDA has changed by -$8.20 M (-5.22%)
What is BioXcel Therapeutics quarterly EBITDA?
The current quarterly EBITDA of BTAI is -$9.78 M
What is the all time high quarterly EBITDA for BioXcel Therapeutics?
BioXcel Therapeutics all-time high quarterly EBITDA is -$528.00 K
What is BioXcel Therapeutics quarterly EBITDA year-on-year change?
Over the past year, BTAI quarterly EBITDA has changed by +$8.96 M (+47.80%)
What is BioXcel Therapeutics TTM EBITDA?
The current TTM EBITDA of BTAI is -$56.15 M
What is the all time high TTM EBITDA for BioXcel Therapeutics?
BioXcel Therapeutics all-time high TTM EBITDA is -$528.00 K
What is BioXcel Therapeutics TTM EBITDA year-on-year change?
Over the past year, BTAI TTM EBITDA has changed by +$109.27 M (+66.05%)